证券代码：002141 证券简称：贤丰控股 贤丰控股股份有限公司投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |-----------------------|-------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 新润通国际融资租赁有限公司 张家铭 | | 人员姓名 | | | | 时间 | 2017 年 11 月 1 | 日 | | 地点 | 现场调研 | | | 上市公司接待人 员姓名 | | 董事长陈文才、副总经理张斌、董事会秘书张志刚 | | 投资者关系活动 | 现场问答： | | | | 1. 公司盐湖卤水提锂技术来源？ | | | 主要内容介绍 ...

Group 1: Strategic Partnerships and Market Positioning - The company signed a strategic cooperation agreement with Bolivia's lithium industry authority, which is significant for its business expansion [2][4] - Bolivia holds the world's largest lithium reserves, with a total of 21 million tons, primarily located in the Uyuni and Coipasa salt flats [4][5] - The partnership aims to share resources, technology, and funding to create a complete lithium extraction and battery production industry chain [5] Group 2: Technological Advancements and Production Capacity - The company’s lithium extraction project in Huizhou has an annual capacity of 4,500 tons and commenced production on November 19, 2018 [5] - The company has developed several patented technologies, including initial extraction and enrichment methods, which are crucial for lithium production [5][6] - The production cost of lithium carbonate is reduced by 10% compared to similar domestic products, with a low loss rate of lithium during the process [7][8] Group 3: Future Development Plans - The company plans to expand its business into the lithium battery supply chain, focusing on resource recovery and recycling [10] - Future strategies include diversifying into industrial-grade lithium carbonate, battery-grade lithium carbonate, and lithium hydroxide [10] - The company aims to enhance its fine wire business by targeting high-end industries such as automotive and aerospace [11][12]

Group 1: Lithium Extraction Technology - The company's lithium extraction technology from salt lake brine is sourced from a partnership with Shenzhen Juneng Yongtuo Technology Development Co., Ltd [2] - The choice of using enriched material for lithium extraction instead of solvent extraction or membrane methods significantly reduces lithium loss and improves carbonization efficiency [2] - The technology enhances the capacity of single reaction towers, reduces wear on equipment, and lowers associated costs, thereby decreasing investment amounts [2] Group 2: Lithium Demand and Price Forecast - The demand for lithium primarily comes from 3C products, electric vehicles, and energy storage, with a growth rate of around 10% in 2015 and 2016 [3] - The total demand for lithium is expected to maintain an annual growth rate of over 10% from 2017 to 2020 due to low current production capacity and delayed release of new capacity [3] - The company anticipates a significant likelihood of price increases for lithium products in the future, maintaining a strong price level for an extended period [3] Group 3: Resource Holdings and Strategic Partnerships - In 2017, the company signed strategic cooperation agreements with China Agricultural Production Materials Group and Shenzhen Zhonghang Resources Co., Ltd, acquiring a 36% stake in Mangya Xingyuan Potash Fertilizer Co., Ltd [3] - The mining area of the Mangya Xingyuan Potash Fertilizer is 145.468 square kilometers, with plans for future expansion of approximately 600 square kilometers [3] - The company is also involved in a partnership with Qinghai Zhonghang Resources, which has a mining area of 2.84 million square kilometers [3] Group 4: Production Capacity and Business Development - The first phase of the enriched material production line is expected to complete construction this year, with future expansion to 4,500 tons [3] - The company is in the process of registering a 10,000-ton lithium carbonate project, with a pilot line of 100 tons expected to be completed by the end of this year or early next year [3] - The fine wire business achieved a revenue of 1.158 billion yuan and a net profit of 24.82 million yuan in 2017, marking a historical high [4]

Group 1: Event Details - The company will participate in the 2022 Guangdong Listed Companies Investor Online Reception Day [2] - The event will be held on September 22, 2022, from 15:50 to 16:50 [2] - The online platform for the event is provided by Shenzhen Qianjing Network Co., Ltd. [2] Group 2: Participants - The company's chairman, Ms. Han Taozi, will be present [2] - The general manager, Mr. Ding Chen, will also participate [2] - Other participants include the board secretary and vice general manager, Ms. Liang Danni, and the board member and financial director, Mr. Xie Wenbin [2] Group 3: Investor Engagement - The company aims to enhance interaction and communication with investors [2] - Investors are encouraged to actively participate in the event [2]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[19]. - Net profit attributable to shareholders reached RMB 200 million, up 10% compared to the same period last year[19]. - The company's operating revenue for the first half of 2022 was CNY 598,439,372.45, a decrease of 17.79% compared to the same period last year[25]. - Net profit attributable to shareholders increased by 164.47% to CNY 23,387,289.92, driven by effective asset disposal strategies[25]. - The company expects a revenue growth forecast of 18% for the second half of 2022, driven by new product launches[19]. - The company reported a significant increase in non-recurring gains, primarily from asset disposals and government subsidies totaling CNY 56,702,052.15[30]. - The company reported a net profit of RMB 2,385,180 from the sale of significant assets, reflecting a 59.24% increase compared to previous periods[68]. - The company reported a basic and diluted earnings per share of CNY 0.0206 for the first half of 2022, up from CNY 0.0078 in the same period of 2021[154]. - The total comprehensive income for the first half of 2022 was CNY 55,290,329.18, compared to CNY 2,023,751.74 in the same period of 2021[154]. Investment and Development - The company plans to invest RMB 300 million in new product development and technology research in the upcoming year[19]. - The company has invested over CNY 500 million in research and development, obtaining numerous qualifications and honors, including 13 national invention patents and 11 utility model patents[40]. - The company maintains a research and development investment of over 10% of its sales revenue annually, with a dedicated R&D center of over 2,000 square meters and approximately 60 R&D personnel[42]. - The company is actively developing a 50,000-ton high-nickel ternary precursor project and plans to quickly initiate related businesses by leasing production lines from Hubei Jiangchen New Energy Technology Co., Ltd.[36]. - The company launched new products including inactivated vaccines for porcine parvovirus and streptococcus, enhancing its product line and aiming for zero defects in product quality through new GMP certification[35]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 20% market share by 2025[19]. - User data indicates a growth of 25% in active users, reaching 5 million by the end of June 2022[19]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[19]. Risk Management - The management has identified key risks including market competition and supply chain disruptions, with strategies in place to mitigate these risks[19]. - The company plans to enhance its market risk management and adjust strategies in response to market changes[77]. - The biological vaccine business is subject to market competition and cyclical risks associated with the livestock and aquaculture industries[76]. - The new energy sector faces risks from fluctuating raw material prices, including copper and nickel, influenced by global events like the COVID-19 pandemic and the Russia-Ukraine conflict[77]. Environmental and Social Responsibility - Environmental protection measures at Shiji Biological are functioning well, with no reported exceedances of pollution standards[86]. - The wastewater treatment facility has a processing capacity of 700 m³/d, ensuring compliance with discharge standards[87]. - The company actively participates in public welfare activities, including donations to impoverished students and local charities[97]. - The company has implemented a third-party monitoring scheme for water, air, and noise, with all tests passing compliance in the first half of the year[90]. Financial Position and Assets - The total assets at the end of the reporting period were CNY 1,392,674,517.92, a slight decrease of 0.16% from the previous year[25]. - The company's total liabilities decreased to CNY 441,667,542.16 from CNY 545,385,253.71, a reduction of approximately 19%[146]. - The total equity attributable to shareholders increased to CNY 842,051,213.18 from CNY 803,637,142.31, reflecting a growth of about 4.7%[146]. - The company reported a significant decrease in accounts payable, which fell to CNY 52,240,188.77 from CNY 89,272,868.09, a decline of approximately 41.5%[145]. Corporate Governance and Compliance - The company will not distribute cash dividends or issue bonus shares for the half-year period[82]. - The semi-annual financial report has not been audited[102]. - The company has not experienced any major litigation or arbitration matters during the reporting period[104]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[100]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 46,889[131]. - Guangdong Xianfeng Holdings Co., Ltd. holds 26.03% of the shares, totaling 295,358,647 shares, which are pledged[131]. - The largest shareholder, Guangdong Xianfeng Holdings, has 292,200,000 shares pledged[131]. - The company has not conducted any repurchase transactions during the reporting period[132].

Financial Performance - The company's revenue for Q1 2022 was ¥274,449,534.28, a decrease of 12.26% compared to ¥312,798,252.98 in the same period last year[2] - Net profit attributable to shareholders was ¥17,608,180.89, representing a significant increase of 275.20% from ¥4,693,041.82 in the previous year[2] - Basic and diluted earnings per share increased by 278.05% to ¥0.0155 from ¥0.0041 in the same period last year[2] - Net profit for Q1 2022 reached CNY 15,563,776.00, significantly up from CNY 1,752,108.95 in Q1 2021, marking an increase of 786.5%[20] - Basic earnings per share for Q1 2022 were CNY 0.0155, compared to CNY 0.0041 in Q1 2021, representing an increase of 278.0%[21] Cash Flow - The net cash flow from operating activities decreased by 53.82% to ¥7,385,550.42 from ¥15,993,341.53 year-on-year[2] - Total cash inflow from operating activities is ¥317,568,441.61, down from ¥354,535,163.78, reflecting a decline of 10.4%[22] - Cash outflow from operating activities totaled ¥310,182,891.19, compared to ¥338,541,822.25 in the previous period, indicating a decrease of 8.4%[24] - The net cash flow from investment activities increased significantly to ¥35,046,952.79 from ¥11,265,541.72, representing a growth of 211.5%[24] - The net cash flow from financing activities turned negative at -¥16,645,350.99, compared to a positive ¥95,869,066.04 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,344,120,842.74, down 3.64% from ¥1,394,959,827.53 at the end of the previous year[2] - Total liabilities decreased to CNY 480,216,122.18 from CNY 545,385,253.71, reflecting a reduction of 11.9%[17] - The company's equity attributable to shareholders increased by 2.04% to ¥820,011,693.94 from ¥803,637,142.31 at the end of the previous year[2] - The company's equity attributable to shareholders increased to CNY 820,011,693.94 from CNY 803,637,142.31, showing a growth of 2.3%[17] Expenses - The company reported a significant increase in sales expenses by 97.31% to ¥7,488,013.89, mainly due to the consolidation of Shiji Biological[8] - Research and development expenses rose by 62.54% to ¥8,837,442.94, reflecting increased investment in innovation[8] - Research and development expenses for Q1 2022 were CNY 8,837,442.94, up from CNY 5,437,133.59 in the previous year, indicating a rise of 62.5%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 45,250[10] - Guangdong Xianfeng Holdings Co., Ltd. holds 26.03% of shares, totaling 295,358,647 shares, with 292,200,000 shares pledged and 295,358,647 shares frozen[10] - Xianfeng Holdings Group Co., Ltd. owns 14.03% of shares, amounting to 159,152,000 shares, with 114,000,000 shares frozen[10] Other Information - Non-recurring gains and losses totaled ¥29,180,871.47, primarily due to the disposal of assets by Huizhou New Energy[5] - The company has no plans to reclassify any non-recurring gains and losses as regular gains and losses[6] - The company has received a civil ruling from the Shenzhen Intermediate People's Court regarding a contract dispute, leading to the lifting of property preservation measures on its assets[12] - The company is in the process of handling the lifting of property preservation measures for its land and buildings located in Zhuhai[12] - Other comprehensive income after tax for Q1 2022 was CNY -1,233,629.26, compared to CNY 2,024,816.80 in Q1 2021[21]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 20%[17]. - The company's operating revenue for 2021 was ¥1,469,710,678.10, representing a 52.51% increase compared to ¥963,661,415.21 in 2020[6]. - The net profit attributable to shareholders for 2021 was ¥29,190,245.40, a significant turnaround from a loss of ¥544,631,457.22 in 2020, marking a 105.36% improvement[6]. - The net profit after deducting non-recurring gains and losses was ¥15,201,547.00 in 2021, compared to a loss of ¥209,359,983.33 in 2020, reflecting a 107.26% increase[6]. - The net cash flow from operating activities for 2021 was ¥10,483,842.83, a 109.27% increase from a negative cash flow of ¥113,072,205.75 in 2020[6]. - The company reported a basic earnings per share of ¥0.0257 for 2021, a significant recovery from a loss of ¥0.4800 in 2020[6]. - The weighted average return on equity for 2021 was 3.67%, a substantial improvement from -48.89% in 2020[6]. - The company achieved operating revenue of 1,469.71 million yuan, a year-on-year increase of 52.51%[46]. - The net profit attributable to shareholders was 29.19 million yuan, up 105.36% compared to the previous year[46]. - The company’s cash flow from operating activities increased by 109.27% to 10.48 million yuan[46]. Market Expansion and Strategy - The company has provided a positive outlook for 2022, projecting a revenue growth of 25% based on current market trends and user acquisition strategies[17]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[17]. - The company plans to expand its business in the lithium-ion battery supply chain by establishing a joint venture with BetterRay to develop precursor materials for battery cathodes[32]. - The company plans to continue expanding its market presence and product lines, focusing on both domestic and international markets[54]. - The company is actively pursuing market expansion and new product development strategies to enhance its competitive position[100]. Research and Development - The company has allocated 100 million RMB for research and development in new technologies, aiming to improve product efficiency and sustainability[17]. - The company invested over 500 million yuan in R&D, with annual R&D expenditure consistently above 10% of sales revenue[44]. - Research and development expenses increased by 69.30% to CNY 59,706,177.88, mainly due to the integration of Shiji Biological's R&D costs[68]. - The number of R&D personnel rose by 21.95% to 150, with a significant increase in the number of bachelor's and master's degree holders[70]. - R&D investment amounted to CNY 74,325,097.20, a 96.11% increase compared to the previous year, accounting for 5.06% of total revenue[71]. Acquisitions and Divestitures - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's production capacity by 30%[17]. - The company completed the acquisition of Shiji Biological, enhancing its presence in the veterinary vaccine sector[47]. - The company plans to divest its micro-fine enameled wire business, transferring all shares for 552.43 million yuan[47]. - The company acquired Shiji Biological and Nanjing Shiji in March 2021, expanding its veterinary vaccine business, primarily focusing on pig vaccines[62]. - The acquisition of Shiji Biological, effective April 1, 2021, contributed to the increase in sales and revenue[56]. Environmental and Social Responsibility - The company emphasizes corporate social responsibility, focusing on environmental protection and stakeholder engagement[165]. - The company received a special fund of 250,000 RMB from the Jinwan District Finance Bureau for its environmental initiatives[158]. - The company has established an education poverty alleviation fund to support impoverished students, ensuring educational equity and promoting healthy development[166]. - The company has implemented low-nitrogen burners in its gas boilers to reduce nitrogen oxide emissions, with ongoing installation of additional low-nitrogen boilers[157]. - The company confirmed that it is a key pollutant discharge unit as per environmental protection department announcements[155]. Governance and Management - The board of directors has confirmed that all financial reports are accurate and complete, with no significant omissions or misleading statements[4]. - The company has established specialized committees within the board, including a strategy committee and an audit committee, to enhance governance[112]. - The company emphasizes investor relations management, ensuring effective communication and transparency with investors[113]. - The company has a fully independent financial department with a standardized accounting system, ensuring independent financial decision-making and compliance with tax obligations[116]. - The company appointed Ding Chen as the new General Manager on December 15, 2021, replacing Han Taozi, to enhance long-term strategic development and governance[120]. Risks and Challenges - The company has identified potential risks in the supply chain and is implementing measures to mitigate these risks, ensuring operational stability[5]. - The company faces increased financial pressure due to rising copper prices, which are critical for its enameled wire production, impacting its business expansion[39]. - The company faces risks related to the sale of assets, including potential delays in regulatory approvals and the impact on revenue from exiting the fine enameled wire business[104]. - The company has identified risks in the new energy sector due to potential unfavorable changes in government policies affecting the electric vehicle market[105]. - The veterinary vaccine business is subject to market risks, including increased competition and changing regulatory standards that could impact demand[107]. Internal Control and Compliance - The internal control system has been updated and improved according to relevant regulations, effectively preventing operational risks[147]. - The company reported that there were no significant internal control deficiencies identified during the reporting period[148]. - The company has maintained effective internal control over financial reporting as of December 31, 2021, according to the internal control audit report[151]. - The company has a total of 100% of its assets and revenue included in the internal control evaluation report[149]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[146].

Financial Performance - The company's revenue for Q3 2021 reached ¥391,220,245.26, representing a 45.49% increase year-over-year[3] - Net profit attributable to shareholders was ¥9,147,217.48, a significant increase of 119.96% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥7,878,110.93, up 132.98% year-over-year[3] - Revenue for the first nine months reached ¥1,119,193,502.61, a 71.64% increase compared to ¥652,048,178.58 in the same period last year, driven by increased orders from Zhuhai Rongsheng and the inclusion of Chengdu Shiji's revenue[8] - Total operating revenue for the third quarter of 2021 reached ¥1,119,193,502.61, a significant increase from ¥652,048,178.58 in the same period of 2020, representing a growth of approximately 71.5%[17] - The company's net profit for the third quarter of 2021 was ¥30,804,840.88, a recovery from a loss of ¥223,116,987.21 in the same quarter of 2020[17] - The total profit for Q3 2021 was 30,611,610.12 CNY, compared to a loss of 223,209,210.13 CNY in the same period last year[19] - The net profit for Q3 2021 was 22,784,839.13 CNY, recovering from a net loss of 218,769,707.84 CNY in Q3 2020[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,474,129,543.01, reflecting a 26.29% increase from the end of the previous year[3] - Total assets as of September 30, 2021, amounted to ¥1,474,129,543.01, up from ¥1,167,240,757.94 at the end of 2020, representing a growth of approximately 26.2%[17] - Total liabilities increased to ¥619,052,267.02 from ¥418,612,402.20, indicating a rise of about 47.8%[16] - Total non-current assets amounted to CNY 406,629,533.25, with fixed assets contributing CNY 222,507,269.69[26] - Total liabilities reached CNY 418,612,402.20, with current liabilities accounting for CNY 367,178,995.26[27] Cash Flow - The company reported a net cash flow from operating activities of -¥15,249,972.12, a decrease of 74.34% compared to the previous year[3] - The cash flow from operating activities for Q3 2021 was -15,249,972.12 CNY, an improvement from -59,424,213.12 CNY in Q3 2020[22] - The total cash inflow from operating activities was 1,215,146,068.87 CNY, significantly higher than 634,128,033.10 CNY in the previous year[22] - The cash flow from investing activities generated a net inflow of 20,923,998.20 CNY, down from 157,095,163.60 CNY in Q3 2020[22] - The company reported a total cash outflow from financing activities of 101,945,104.67 CNY in Q3 2021, compared to 153,031,497.50 CNY in Q3 2020[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,556[11] - The largest shareholder, Guangdong Xianfeng Holdings Co., Ltd., holds 26.03% of shares, totaling 295,358,647 shares, with 292,200,000 shares pledged[11] - The second-largest shareholder, Xianfeng Holdings Group Co., Ltd., holds 14.03% of shares, totaling 159,152,000 shares, with 114,000,000 shares pledged[11] Strategic Developments - The company reached a mediation agreement regarding a financing lease contract dispute on October 18, 2021, which led to adjustments in previously accrued interest expenses[12] - The company has disclosed significant matters, including a notice of share reduction by shareholders holding more than 5% of shares, which exceeded 1%[12] - The company is continuing to use idle self-owned funds for cash management as of August 14, 2021[12] - The company is progressing with a merger fund investment as of August 11, 2021[12] - The company has announced the transfer of land use rights and ownership of buildings on August 14, 2021[12] - The company has disclosed plans for share reduction by major shareholders on July 1, 2021[12] - The company has made progress in acquiring equity and external investments as of July 2, 2021[12] Research and Development - R&D expenses increased by 50.70% to ¥41,482,078.88, up from ¥27,526,386.18, as Zhuhai Rongsheng intensified its R&D investments[8] - The company reported research and development expenses of ¥41,482,078.88 for the third quarter of 2021, compared to ¥27,526,386.18 in the same period of 2020, reflecting an increase of about 50.5%[17] Tax and Other Financial Metrics - Tax expenses increased by 276.30% to ¥7,826,770.99, compared to a tax benefit of -¥4,439,502.29 in the previous year, driven by profitability at Zhuhai Rongsheng and Chengdu Shiji[8] - Other income grew by 44.13% to ¥7,880,957.45, compared to ¥5,468,112.33, mainly due to higher government subsidies received during the reporting period[8] - Investment losses improved by 93.66%, with losses of ¥6,632,305.76 compared to ¥104,618,783.81 in the previous year, attributed to changes in the calculation method for last year's investment losses[8] - The fair value change income was ¥5,491,576.99, a significant recovery from a loss of ¥17,195,579.96, due to changes in the fair value of trading financial assets[8] - Other payables surged by 1240.78% to ¥278,497,157.72, up from ¥20,771,280.12, mainly due to strategic cooperation intention funds received from Zhuhai Rongsheng and payments due for Chengdu Shiji's equity transfer[8] - Deferred income tax liabilities rose by 87.12% to ¥13,894,401.20, compared to ¥7,425,364.71, primarily due to asset appraisal increases from Chengdu Shiji[8] - Minority interests increased by 277.82% to ¥57,780,851.80, compared to -¥32,494,465.70 in the previous year, mainly due to the consolidation of Chengdu Shiji[8] Audit and Compliance - The company has not conducted an audit for the third quarter report, which may affect the reliability of the financial data presented[29] - The implementation of the new leasing standards did not have a significant impact on the company's consolidated financial statements[28] - The company recognized right-of-use assets and lease liabilities amounting to CNY 9,876,515.35 and CNY 3,673,340.39 respectively as of January 1, 2019, and January 1, 2020[28]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥727,973,257.35, representing a 90.00% increase compared to ¥383,145,018.41 in the same period last year[23]. - The net profit attributable to shareholders of the listed company reached ¥8,843,196.16, a significant turnaround from a loss of ¥156,793,168.74 in the previous year, marking a 105.64% improvement[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,964,707.53, compared to a loss of ¥26,189,320.70 in the same period last year, reflecting a 115.14% increase[23]. - The basic earnings per share were ¥0.0078, recovering from a loss of ¥0.1382 per share in the previous year, indicating a 105.64% improvement[23]. - The company reported a net profit of ¥4,752,581.00 for the first half of 2021, a turnaround from a net loss of ¥147,709,550.51 in the first half of 2020[159]. - The gross profit margin improved to 0.6% in the first half of 2021, compared to a negative margin in the previous year[158]. - The company reported a comprehensive loss of CNY 11,735,253.64 during the period, indicating a significant decline in profitability compared to the previous period[186]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,534,729,848.38, which is a 31.48% increase from ¥1,167,240,757.94 at the end of the previous year[24]. - The total liabilities increased to CNY 690.29 million as of June 30, 2021, compared to CNY 418.61 million at the end of 2020, a 65% rise[152]. - The company's total assets reached CNY 1.53 billion, compared to CNY 1.17 billion at the end of 2020, a 31% increase[152]. - The total equity at the end of the reporting period is CNY 1,190,788,115.23, down from CNY 1,202,523,368.87 at the beginning of the year, reflecting a decrease of approximately 1.0%[186]. - The retained earnings at the end of the current period are CNY -233,092,297.18, indicating accumulated losses[183]. Cash Flow - The company reported a negative net cash flow from operating activities of ¥3,370,154.83, a decline of 135.72% compared to a positive cash flow of ¥9,434,015.51 in the same period last year[23]. - The net cash flow from financing activities was 53,144,375.54 yuan, a turnaround from -52,752,804.44 yuan in the same period of 2020[166]. - Total cash inflow from operating activities was 792,972,614.65 yuan, compared to 408,281,265.71 yuan in the first half of 2020, representing an increase of approximately 94%[166]. - Cash outflow from operating activities totaled 796,342,769.48 yuan, up from 398,847,250.20 yuan in the previous year, indicating a 99.6% increase[166]. Business Segments - The micro-fine enameled wire business achieved a revenue of 697.08 million yuan, representing a year-on-year growth of 81.98%, and a net profit of 27.92 million yuan, up 372.11%[33]. - The veterinary vaccine business generated a revenue of 78.49 million yuan, a 67.27% increase compared to the previous year, with a net profit of 34.82 million yuan, reflecting a growth of 442.63%[34]. - The enameled wire segment accounted for 95.99% of total revenue, with sales reaching ¥698,802,645.90, an increase of 82.39% year-on-year[42]. Research and Development - Research and development expenses rose by 39.52% to ¥24,043,508.96, driven by increased investment from subsidiaries[38]. - The company has established various research platforms for vaccine development, including gene engineering and large-scale fermentation processes[36]. - The veterinary vaccine business is focusing on multi-valent vaccines and gene-engineered vaccines as key R&D projects[34]. Environmental and Social Responsibility - The company emphasizes environmental protection and clean production, with no major environmental or social safety issues reported during the period[95]. - The company has established an emergency response plan for environmental incidents, with a validity period from December 4, 2018, to December 3, 2021[84]. - The company donated a total of 10,348.93 yuan for educational support to impoverished students in the first half of 2021[96]. Governance and Shareholder Relations - The company has implemented a robust governance structure to protect shareholder rights and enhance communication with investors[90]. - The company held two shareholder meetings in the first half of 2021, facilitating online voting for minority investors[90]. - The company has no significant litigation or arbitration matters during the reporting period[105]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[161]. - The company has not provided specific future guidance or outlook for the upcoming periods[178].

Financial Performance - The company's operating revenue for Q1 2021 was CNY 312,798,252.98, representing a 96.81% increase compared to CNY 158,936,440.83 in the same period last year[8] - The net profit attributable to shareholders for Q1 2021 was CNY 4,693,041.82, a significant increase of 623.85% from CNY 648,343.31 in the previous year[8] - The net cash flow from operating activities reached CNY 15,954,968.13, marking a 276.59% improvement from a negative cash flow of CNY 9,035,076.61 in the same period last year[8] - Basic earnings per share for Q1 2021 were CNY 0.0041, up 583.33% from CNY 0.0006 in the previous year[8] - The company reported a net loss of ¥442,789,335.17 as of March 31, 2021, slightly improved from a loss of ¥447,404,127.94 at the end of 2020[33] - The total operating revenue for the first quarter of 2021 was CNY 312,798,252.98, an increase of 96.5% compared to CNY 158,936,440.83 in the same period last year[38] - The total operating costs amounted to CNY 315,614,191.38, up 71.4% from CNY 184,162,667.90 year-on-year[39] - The net profit for the first quarter was CNY 1,752,108.95, compared to a net loss of CNY 939,025.89 in the previous year[40] - The company reported a total comprehensive income of CNY 3,776,925.75, compared to a loss of CNY 1,063,193.51 in the previous year[40] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,480,632,200.59, reflecting a 26.85% increase from CNY 1,167,240,757.94 at the end of the previous year[8] - The total assets increased to CNY 1,596,225,517.88, up from CNY 1,262,028,385.96 year-on-year, reflecting a growth of 26.5%[36] - The total liabilities of the company as of March 31, 2021, were ¥631,220,477.09, up from ¥418,612,402.20 at the end of 2020, indicating an increase of about 50.7%[32] - The total liabilities rose to CNY 586,252,991.24, compared to CNY 249,755,661.94 in the previous year, marking an increase of 134.7%[36] - The company's inventory rose to ¥186,543,573.79 from ¥132,252,604.59, marking an increase of approximately 41%[30] Cash Flow - Cash and cash equivalents increased by 333.48% to ¥159,953,811.57 due to the consolidation of Chengdu Tianbang Biological Products Co., Ltd. and Nanjing Shiji Biotechnology Co., Ltd.[16] - Cash flow from operating activities increased by 103.69% to ¥341,530,892.02, attributed to higher sales in the enameled wire business[17] - The cash flow from operating activities generated a net inflow of ¥15,993,341.53, compared to a net outflow of ¥9,035,076.61 in the previous year[46] - The financing activities resulted in a net cash inflow of ¥95,869,066.04, compared to a net outflow of ¥4,214,535.46 in the previous year[47] Government Subsidies - The company received government subsidies amounting to CNY 5,663,656.07 during the reporting period[9] - The company received government subsidies amounting to ¥5,663,656.07, a 63.32% increase compared to the previous year[17] Shareholder Information - The total number of shareholders at the end of the reporting period was 45,763[12] - The net assets attributable to shareholders increased to CNY 787,744,998.41, a slight rise of 0.85% from CNY 781,105,388.84 at the end of the last year[8] Strategic Outlook - The company plans to continue expanding its market presence through strategic acquisitions and investments in new technologies[19] - The company has not disclosed any key performance indicators in the available documents[58][59] - Future outlook and performance guidance are not detailed in the available reports[58][59] Operational Integrity - The company has no overdue or unrecovered amounts related to entrusted financial management, indicating a stable financial management strategy[25] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period, ensuring financial integrity[26] - The company has not reported any significant contracts or major operational changes during the reporting period, suggesting stability in operations[27] - The company has not conducted any research, communication, or interview activities during the reporting period, indicating a focus on internal operations[27]